Every route · Chronic Kidney Disease · Kidney and urologic

Jardiance for Chronic Kidney Disease: every route to paying for it

6 of 6 routes have a dated fact in our data for Jardiance and Chronic Kidney Disease. Where we found nothing the page says so; that does not mean none exists.

The order is fixed and is not a ranking. The FDA label first, then public Medicare facts, then the manufacturer, then charities, then research access. It does not say which route is best for you, and no saving is computed.

A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.

The routes, in order

1
Why this drug and this condition are paired
... to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
A sentence about reducing the risk of the condition. From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.
Label on openFDA, read 2026-11-10 · receipt
2
Medicare Part D: the yearly out-of-pocket threshold
Found in our data
CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).
A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.
CMS Table V-2, read 2026-11-08
3
Medicare negotiated price
Found in our data
CMS lists $202.33 for a 30-day supply, effective 2027-01-01.
The price CMS lists for the drug, not what you pay. What you pay depends on your plan and your cost sharing.
CMS negotiated prices, read 2026-11-06
4
Manufacturer and foundation programs
Found in our data
- Jardiance Savings (via Boehringer Ingelheim/Lilly) status not recorded
- Heart Medication Assistance (Multiple Programs) status not recorded
- Diabetes Medication Assistance (Multiple Programs) status not recorded
- Boehringer Ingelheim Cares Foundation Limited the program's own page, read 2026-11-06
A status is what the program's page says about taking applications, not whether you qualify. Each program has its own eligibility rules.
5
Charitable funds for Chronic Kidney Disease
Found in our data
We hold 2 funds for Chronic Kidney Disease: 0 open and 2 not open, read 2026-11-08.
Every fund, with its award level, insurance supported and source, is on the Chronic Kidney Disease page. A fund pays for a condition's costs, not necessarily this drug.
6
Clinical trial access
Found in our data
ClinicalTrials.gov lists 94 recruiting interventional trials that name this ingredient (read 2026-11-07).
A trial is research, not treatment access for everyone, and a listing is not a recommendation.
ClinicalTrials.gov, read 2026-11-07 · receipt

More about Jardiance and Chronic Kidney Disease

Edition 2026-11, root 006ab9a329709cbe. See the licence page.

Questions

Is Jardiance approved for Chronic Kidney Disease?

This page cannot say that. The Indications and Usage text of the drug's FDA label names Chronic Kidney Disease, which is the evidence for pairing them. Read the label and ask your prescriber.

What are the routes on this page?

Why this drug and this condition are paired; Medicare Part D: the yearly out-of-pocket threshold; Medicare negotiated price; Manufacturer and foundation programs; Charitable funds for Chronic Kidney Disease; Clinical trial access. For this drug and condition we found why this drug and this condition are paired, medicare part d: the yearly out-of-pocket threshold, medicare negotiated price, manufacturer and foundation programs, charitable funds for chronic kidney disease, clinical trial access.

Is the order a ranking?

No. The order is fixed: the label, then public Medicare facts, then the manufacturer, then charities, then research access. It does not say which route is best or cheapest for you, and no saving is computed.

How current is this?

Each route shows the date we read its source. Statuses are what the source said on that date.